Price to earnings forward of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT
This article provides the "Price to earnings forward" for 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) on TradingView. It appears to be an auto-generated or financial data stub page, displaying the company's stock information and financial metrics within the TradingView platform.
FDMT (NASDAQ: FDMT) CLO sells 6,566 shares, exercises options under 10b5-1 plan
4D Molecular Therapeutics Chief Legal Officer Scott Bizily sold 6,566 shares of common stock at $14.00 per share on June 30, 2026, as part of a Rule 10b5-1 trading plan. On the same date, he exercised stock options for a total of 6,566 shares at exercise prices of $6.49 and $4.14 per share. These transactions were officially filed with the SEC on July 2, 2026.
FDMT - 4D Molecular Therapeutics Inc Latest SEC Filings
This page provides a detailed financial overview and snapshot of 4D Molecular Therapeutics Inc (FDMT), including its latest stock performance, key financial metrics, insider and institutional ownership, and valuation ratios. The data highlights the company's recent strong performance in stock price and sales growth, alongside its negative profitability metrics and significant short interest.
Form 144 4D Molecular Therapeutics For: 30 June By Investing.com
This article from Investing.com reports the filing of Form 144 for 4D Molecular Therapeutics activity as of June 30. The content is very brief, serving primarily as a notice of the filing. It is surrounded by extensive financial market data, news headlines, and navigational elements typical of a financial news portal.
FDMT (NASDAQ: FDMT) insider 10b5-1 sale of 9,810 shares for $117,720
An affiliate of 4D Molecular Therapeutics, Inc. (FDMT) filed a Form 144 detailing insider sales. The filing reports a 10b5-1 sale by Scott Bizily of 9,810 shares for $117,720 on June 23, 2026, alongside an exercise of stock options for 5,752 shares and an Employee Stock Purchase Plan sale of 814 shares. These activities are characterized as routine insider dispositions, with the company's shares outstanding listed at 52,276,254 as of June 30, 2026.
4D Molecular Therapeutics to present 2-year Phase 2b trial results of gene therapy 4D-150 for wet AMD at ASRS 2026
4D Molecular Therapeutics announced it will present two-year follow-up data from its PRISM Phase 2b clinical trial of 4D-150, a gene therapy for wet age-related macular degeneration (AMD), at the 44th Annual Scientific Meeting of the American Society of Retina Specialists in July 2026. The therapy, 4D-150, is designed to provide sustained delivery of anti-VEGF biologics with a single intravitreal injection, aiming to reduce the treatment burden for patients. Dr. Carl Awh will deliver the presentation, highlighting 4DMT's commitment to advancing durable retinal disease treatments.
4DMT to present 2-year PRISM trial follow-up at retina meeting
4D Molecular Therapeutics (Nasdaq: FDMT) has announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists on July 18, 2026. The presentation will feature two-year follow-up data from the PRISM Phase 2b trial of its investigational intravitreal gene therapy, 4D-150, for neovascular AMD. The company's recent news, including clinical and financing updates, has generally seen positive stock price movements.
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
4D Molecular Therapeutics (4DMT) announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) in Montreal, Canada, from July 15-18, 2026. The presentation will provide a 2-year follow-up on the PRISM Phase 2b clinical trial evaluating investigational 4D-150, an intravitreal gene therapy, for neovascular AMD. 4DMT is a late-stage biotechnology company developing durable and disease-targeted therapeutics, with 4D-150 being a lead product candidate for retinal vascular diseases.
4DMT completes enrollment in 4FRONT-2, global phase 3 trial of 4D-150 in wet AMD
4D Molecular Therapeutics (4DMT) has completed enrollment in 4FRONT-2, a global Phase 3 trial for its gene therapy 4D-150 in patients with wet age-related macular degeneration (AMD). This over-enrollment, completed four months ahead of schedule, underscores significant interest in a durable alternative to frequent anti-VEGF injections. 4D-150, which delivers aflibercept and anti-VEGF-C, aims to be a foundational therapy for wet AMD and is also being developed for diabetic macular edema (DME), with Phase 3 results expected in late 2027.
4DMT Completes 4FRONT-2 Enrollment for 4D-150 Gene Therapy in Wet AMD
4D Molecular Therapeutics has completed enrollment for its global Phase 3 trial, 4FRONT-2, for the gene therapy candidate 4D-150 in wet age-related macular degeneration, four months ahead of schedule. The trial aims to achieve non-inferiority in visual acuity compared to aflibercept and will notably compare the number of injections required, seeking to validate 4D-150's potential for sustained anti-VEGF expression with a single injection. Topline data for 4FRONT-2 is expected in H2 2027, with a similar North American trial, 4FRONT-1, anticipating results in H1 2027.
4DMT Secures Strategic Credit Facility for up to $200MM from Hercules Capital
4D Molecular Therapeutics (4DMT) has secured a strategic credit facility of up to $200 million from Hercules Capital. This non-dilutive capital is expected to provide 4DMT with increased financial flexibility, supporting its operations into the second half of 2028 and advancing its gene therapy pipeline, including the 4D-150 program. Initially, 4DMT drew $20 million, with additional tranches available upon achieving specific milestones and lender approval.
4D Molecular Therapeutics Shares Rise After New Credit Facility
4D Molecular Therapeutics (NASDAQ:FDMT) shares increased following the announcement of a new Senior Secured Credit Facility worth $175 million from an investment fund managed by Blue Owl Capital. This financing is expected to extend the company's cash runway into 2027 and support the development of its gene therapy programs, particularly the Phase 3 PRISM clinical trial for 4D-150 in wet AMD.
Press Release: 4DMT Secures Strategic Credit Facility for up to $200 Million From Hercules Capital
4D Molecular Therapeutics (4DMT) has secured a strategic credit facility for up to $200 million from Hercules Capital. This financing is intended to support the company's clinical pipeline development, including its lead product candidates, and provide working capital. The facility consists of an initial draw of $50 million, with additional tranches available upon achievement of certain clinical and regulatory milestones.
4DMT SECURES STRATEGIC CREDIT FACILITY FOR UP TO $200 MILLION FROM HERCULES CAPITAL
4D Molecular Therapeutics (4DMT) has secured a credit facility of up to $200 million from Hercules Capital. This funding is intended to support the clinical development and manufacturing of 4DMT's targeted AAV gene therapy pipeline, particularly focusing on late-stage clinical programs. The agreement includes an initial tranche of $40 million and provides additional tranches contingent on specific milestones.
4D Molecular Therapeutics Completes Enrollment for 4Front-2 Global Phase 3 Clinical Trial of 4D-150 in Wet Amd
4D Molecular Therapeutics has completed enrollment for its 4FRONT-2 global Phase 3 clinical trial of 4D-150 for wet age-related macular degeneration (wet AMD) approximately four months ahead of schedule. The trial over-enrolled patients, with final randomization expected in Q3 2026 and topline data anticipated in H2 2027. This rapid enrollment highlights the high unmet medical need for a durable vision-preserving treatment for wet AMD.
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
4D Molecular Therapeutics (4DMT) has secured a strategic credit facility of up to $200 million from Hercules Capital, enhancing its financial strength and operational flexibility. This non-dilutive capital will support the company's gene therapy pipeline, including the Phase 3 development of 4D-150 for wet AMD and DME, and early commercial planning. 4DMT's cash reserves, excluding this facility, are projected to fund operations into the second half of 2028.
4D Molecular Therapeutics (FDMT) signs up to $200M secured loan with Hercules
4D Molecular Therapeutics, Inc. (FDMT) has secured a senior loan of up to $200 million from Hercules Capital, with an initial draw of $20 million and additional tranches tied to milestones. The loan matures on June 1, 2031, carries floating interest rates with floors of 8.75% to 9.25% and is secured by substantially all company assets, including intellectual property. The agreement includes financial and performance covenants, which tie cash requirements and other thresholds to market capitalization, outstanding obligations, and FDA approval of lead product candidates.
4DMT finishes Phase 3 enrollment for wet AMD gene therapy trial
4D Molecular Therapeutics (4DMT) has completed enrollment for its 4FRONT-2 global Phase 3 clinical trial for 4D-150 in wet AMD, approximately four months ahead of schedule and with over 500 patients. This milestone, along with the ongoing 4FRONT-1 trial, positions 4DMT to potentially establish 4D-150 as a foundational gene therapy for retinal vascular diseases, aiming to reduce the burden of frequent injections for patients. The company anticipates topline 52-week data from 4FRONT-2 in the second half of 2027 and from 4FRONT-1 in the first half of 2027, with plans to initiate a Phase 3 trial for diabetic macular edema in Q3 2026.
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
4D Molecular Therapeutics (4DMT) has secured a strategic credit facility of up to $200 million from Hercules Capital to advance its gene therapy pipeline and support commercial planning for 4D-150. An initial $20 million has been drawn, with additional funds available upon meeting certain milestones. This non-dilutive capital is expected to provide greater financial flexibility and extend the company's cash runway into the second half of 2028.
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
4D Molecular Therapeutics (4DMT) announced the completion of enrollment for its 4FRONT-2 global Phase 3 clinical trial of 4D-150 for wet age-related macular degeneration (wet AMD), approximately four months ahead of schedule and with over-enrollment. This marks the second completed Phase 3 trial for 4D-150, which aims to provide a durable treatment for wet AMD by significantly reducing the need for frequent injections. Topline data for 4FRONT-2 is expected in the second half of 2027, with 4FRONT-1 data anticipated in the first half of 2027.
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
4D Molecular Therapeutics (4DMT) has completed enrollment for its 4FRONT-2 global Phase 3 clinical trial of 4D-150 for wet age-related macular degeneration (wet AMD), approximately four months ahead of schedule. This trial, along with the 4FRONT-1 trial, aims to validate 4D-150 as a potential long-lasting treatment to reduce the burden of frequent injections for wet AMD patients. Topline data for 4FRONT-2 is expected in the second half of 2027.
4D Molecular (NASDAQ: FDMT) CLO exercises options, sells 9,810 shares at $12
4D Molecular Therapeutics' Chief Legal Officer, Scott Bizily, exercised options to acquire 9,810 shares at $4.14 per share and then sold all of them on the open market at $12.00 per share on June 23, 2026. Following these transactions, Bizily holds 18,427 common shares directly and 63,785 stock options. The filing also notes 5,023 shares purchased previously through the company’s Employee Stock Purchase Plan.
4D Molecular Therapeutics, Inc. Actuals & Estimates (NASDAQ:FDMT)
This article provides an overview of 4D Molecular Therapeutics, Inc. (FDMT) stock, including its current price, historical performance, analyst forecasts, and key financial metrics. It details the company's market capitalization, earnings, revenue, and future earnings report date, along with answers to frequently asked questions about investing in FDMT.
FDMT Forecast — Price Target — Prediction for 2027
This article provides a forecast for 4D Molecular Therapeutics, Inc. (FDMT) stock, including analyst price targets and ratings. It details the company's current stock performance, historical highs and lows, financial metrics like market cap, revenue, and earnings, and offers technical analysis recommendations.
Form 4 4D Molecular Therapeutics Inc For: 23 June By Investing.com
This article from Investing.com reports on a Form 4 filing for 4D Molecular Therapeutics Inc (FDMT) on June 23, 2026. Form 4s disclose changes in beneficial ownership of company stock by insiders. The article provides the filing date but does not include further details about the transaction.
[144] 4D Molecular Therapeutics, Inc. SEC Filing
This article details a Form 144 SEC filing by 4D Molecular Therapeutics, Inc. (FDMT), indicating a proposed sale of securities. The filing specifies the sale of 9810 shares of common stock by an individual through Morgan Stanley Smith Barney LLC, acquired via the exercise of stock options, with an aggregate market value of $102,220.20 and an approximate sale date of June 23, 2026.
Insider David Kirn sells 114,746 4D Molecular Therapeutics (FDMT) shares
David Kirn, a director and officer at 4D Molecular Therapeutics (FDMT), sold 114,746 shares of common stock at a weighted average price of $10.4653 per share. This transaction was executed under a pre-scheduled Rule 10b5-1 trading plan. Following the sale, Kirn retains a direct holding of 942,485 shares in the company.
Form 4 4D Molecular Therapeutics Inc For: 23 June By Investing.com
This article reports on a Form 4 filing for 4D Molecular Therapeutics Inc. dated June 23, 2026. Form 4s disclose transactions by company insiders, and while the article doesn't detail the specific transaction, it indicates that FDMT's stock was up 11.32% in relation to this news. The piece also includes various financial market data and popular news headlines.
Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?
Shares of 4D Molecular Therapeutics (FDMT) recently jumped 7.9%, driven by investor optimism surrounding its pipeline progress, especially its lead candidate 4D-150 for eye diseases. Despite this rally, the consensus EPS estimate for the coming quarter remains unchanged, leading to a Zacks Rank #3 (Hold). Investors should monitor future developments to see if this momentum can be sustained.
David Kirn reports sale of 1,922 FDMT shares via Goldman Sachs (FDMT)
David Kirn has filed a Form 144 notice to sell 1,922 Class A Common shares of 4D Molecular Therapeutics, Inc. (FDMT) valued at $19,257.86. The sale, dated June 1, 2026, is routed through Goldman Sachs & Co. LLC, with the shares having been originally acquired on December 15, 2020. The filing provides transparent details about the insider transaction without indicating any immediate positive or negative impact on the company.
4D Molecular Therapeutics stockholders elect directors and approve proposals at annual meeting
4D Molecular Therapeutics (NASDAQ:FDMT) held its 2026 Annual Meeting where stockholders elected three Class III directors, ratified PricewaterhouseCoopers LLP as their independent accounting firm, and approved executive compensation on an advisory basis. The company's stock is up 134% over the past year, trading at $10.42, and Jefferies recently lowered its price target to $21.00 while maintaining a Buy rating.
4D Molecular Therapeutics (NASDAQ: FDMT) investors approve directors, auditor and pay
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) held its 2026 Annual Meeting of Stockholders where investors approved the election of three Class III directors: Nancy Miller-Rich, John F. Milligan, Ph.D., and Shawn Cline Tomasello, MBA. Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved, on an advisory basis, the compensation of named executive officers. A significant number of shares, 44,038,022 out of 52,274,735 outstanding, were represented at the virtual meeting.
4D Molecular Therapeutics (FDMT) AGM 2026 Summary
The 4D Molecular Therapeutics (FDMT) Annual General Meeting (AGM) for 2026 was held virtually on June 17, 2026, to maximize stockholder participation and efficiency. Three proposals were presented and approved by shareholders: the election of Class III directors, the ratification of PricewaterhouseCoopers as the independent auditor for 2026, and the advisory approval of executive compensation. The full voting outcomes will be disclosed in a Form 8-K filing with the SEC within four business days.
4D Molecular (NASDAQ: FDMT) grants director 50,000 stock options
Charles Theuer, a director at 4D Molecular Therapeutics (NASDAQ: FDMT), was granted 50,000 stock options as part of his non-employee director compensation. These options have an exercise price of $9.42 per share and expire on June 16, 2036. The options will vest one-third on June 17, 2027, with the remainder vesting monthly until fully vested by June 17, 2029, or immediately upon a Change in Control.
4D Molecular (NASDAQ: FDMT) director gets 50,000 stock options grant
4D Molecular Therapeutics (NASDAQ: FDMT) director Susannah Gray was granted 50,000 stock options with an exercise price of $9.42 per share, expiring on June 16, 2036. These options will vest over time, with one-third vesting on June 17, 2027, and the remainder in equal monthly installments until fully vested on June 17, 2029, provided she continues her service to the company. The grant was automatically issued under the company’s non-employee director compensation program as part of her board service.
4D Molecular (FDMT) grants director 50,000 stock options at $9.42
4D Molecular Therapeutics director Glenn Sblendorio was granted 50,000 stock options with an exercise price of $9.42 per share. These options, part of the company's non-employee director compensation program, are set to expire on June 16, 2036. The options will vest one-third on June 17, 2027, with the remainder vesting monthly until June 17, 2029, or earlier upon a Change in Control.
4D Molecular Therapeutics (FDMT) grants director John F. Milligan 75,000 options
John F. Milligan, a director at 4D Molecular Therapeutics (FDMT), has been granted 75,000 stock options with an exercise price of $9.42 per share. These options are part of the company's non-employee director compensation program, with vesting scheduled to occur over three years, concluding fully by June 17, 2029, and expiring on June 16, 2036. The grant was reported as an insider transaction and falls under automatic vesting terms, including accelerated vesting upon a Change in Control event.
Director at 4D Molecular Therapeutics (NASDAQ: FDMT) receives 50,000 options
Jacob Chacko, a director at 4D Molecular Therapeutics (NASDAQ: FDMT), was granted 50,000 stock options as part of the company's non-employee director compensation program. The options have an exercise price of $9.42 per share and expire on June 16, 2036. They will vest one-third on June 17, 2027, with the remainder vesting monthly until June 17, 2029, provided Chacko continues his service, and will fully vest upon a Change in Control.
4D Molecular Therapeutics Inc (FDMT) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis for 4D Molecular Therapeutics Inc (FDMT), noting its current valuation score of 6.61, which ranks it 317 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -3.67, indicating a significant deviation from its recent high and low P/E values. Key valuation metrics like P/B, P/S, and P/CF are not disclosed by the company, according to the article.
4D Molecular Therapeutics Inc (FDMT) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of 4D Molecular Therapeutics Inc (FDMT), detailing its price momentum, support and resistance levels, and various technical indicators. It shows that the stock's current price momentum score is 7.27, ranking 120th in its industry, and suggests a range-bound swing trading opportunity between resistance at $10.52 and support at $8.24. The analysis includes a breakdown of indicators like MACD, RSI, and moving averages, concluding with a "Buy" signal based on these metrics.
4D Molecular Therapeutics Inc (FDMT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides historical dividend and stock split information for 4D Molecular Therapeutics Inc (FDMT). It states that the company has distributed no dividends over the past five years and lists no historical stock split data. The page also includes current stock performance metrics and market capitalization for FDMT.
4D Molecular Therapeutics Inc
This article provides a revenue breakdown for 4D Molecular Therapeutics Inc (FDMT), detailing its financial performance and regional revenue contributions. It notes that relevant data for business segments and current fiscal years (FY2024, FY2025) has not yet been disclosed by the company, though it does list United States revenue figures for FY2023. The piece also includes stock performance data and market capitalization.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (4DMT) announced that its compensation committee granted 66,900 Restricted Stock Units (RSUs) to seven new non-executive employees on June 9, 2026. These grants were made under the Company’s 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company focused on developing durable and disease-targeted therapeutics, with lead product candidates 4D-150 for retinal vascular diseases and 4D-710 for cystic fibrosis.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (4DMT) announced that its compensation committee granted 66,900 Restricted Stock Units (RSUs) to seven new non-executive employees on June 9, 2026. These grants were made under the company's 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company focused on developing therapies for diseases like wet age-related macular degeneration and cystic fibrosis.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (4DMT) announced that its compensation committee granted 66,900 Restricted Stock Units (RSUs) to seven new non-executive employees on June 9, 2026. These grants were made under the Company’s 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company focused on developing gene therapies for diseases like wet age-related macular degeneration and cystic fibrosis.
Fabry Disease Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 – DelveInsight | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutic
The Fabry Disease market is projected to reach approximately USD 1,700 million in 2024 and is expected to grow significantly by 2034, driven by increasing prevalence and emerging therapies. Key players like Sangamo Therapeutics are advancing gene therapies such as ST-920, with potential accelerated FDA approval. The United States holds the largest market share and diagnosed patient population, with Germany leading in Europe.
FDMT: Gene therapy 4D-150 targets lifelong vision benefit and reduced injections in wet AMD
4D-150, a gene therapy developed by 4D Molecular Therapeutics, Inc. (FDMT), aims to treat wet AMD and diabetic eye disease by providing sustained anti-VEGF expression. This approach is intended to reduce the burden of frequent injections and improve patient outcomes. Phase II data indicates strong efficacy and safety, with Phase III results anticipated next year, positioning the product for significant market impact and integration into current medical practice.
4d molecular therapeutics CEO Kirn sells $19,257 in shares
David Kirn, CEO of 4D Molecular Therapeutics, sold 1,922 shares of company stock for approximately $19,257. This sale was conducted under a pre-arranged 10b5-1 trading plan. The company's stock has seen a 159% return over the past year, and Kirn retains over one million shares.
Insider David Kirn sells 1,922 4D Molecular (NASDAQ: FDMT) shares
David Kirn, a director and officer at 4D Molecular Therapeutics (NASDAQ: FDMT), sold 1,922 shares of common stock at a weighted average price of $10.0197 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on January 9, 2026. Following this sale, Kirn still holds a substantial position of 1,057,231 shares in the company.
4d molecular therapeutics CEO Kirn sells $19,257 in shares
David Kirn, CEO of 4D Molecular Therapeutics, sold 1,922 shares for approximately $19,257, following a 159% stock return over the past year. The sale was part of a pre-arranged trading plan. The company is advancing with its pivotal study for wet age-related macular degeneration, while analyst price targets show mixed opinions, with RBC increasing its target and Jefferies lowering its target.
